David Nierengarten

David Nierengarten

Analyst-Equity presso
Wedbush Securities, Inc.
Finance
Consumer Services
Health Technology

Profilo

Dr. David Nierengarten is a Senior Analyst at Wedbush Securities, Inc. Dr. David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy.
His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models.
In addition, Dr. David Nierengarten, Ph.D.
has results in predicting Dendreon's looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.
Dr. David Nierengarten, Ph.D.
received his B.S.
in Biochemistry from the University of Wisconsin-Madison, and Ph.D.
in Molecular and Cell Biology from the University of California at Berkeley.

Posizioni attive di David Nierengarten

SocietàPosizioneInizio
Analyst-Equity -

Precedenti posizioni note di David Nierengarten

SocietàPosizioneFine
Corporate Officer/Principal 30/11/2010
Analyst-Equity 30/06/2007
Corporate Officer/Principal 30/05/2007
Corporate Officer/Principal 31/12/2004
Vedi nel dettaglio l'esperienza di David Nierengarten

Formazione di David Nierengarten

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

100 +

Relazioni di 1° grado

7

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private7

Finance

Health Technology

Finance

Consumer Services

Consumer Services

Finance

Finance

  1. Mercati
  2. Insiders
  3. David Nierengarten
40% di sconto: I migliori strumenti riservati agli abbonati per identificare i migliori investimenti di domani!
g
:
:
ENTRA ORA